Glucagon Mechanism of Action: In-depth Analysis
Title: Glucagon Mechanism of Action: In-depth Analysis Abstract: Glucagon, a 29-amino acid peptide hormone, exerts its mechanism of action via binding to the G-protein-coupled glucagon receptor (GCGR), activating adenylate cyclase and increasing intracellular cAMP. This cascade stimulates hepatic glycogenolysis and gluconeogenesis, elevating blood glucose. In the peptide market, glucagon-based products (e.g., Eli Lilly’s Glucagon, Xeris’ Gvoke) show distinct pharmacokinetic profiles: Gvoke’s non-aqueous formulation offers superior stability and room-temperature storage versus traditional lyophilized kits. Current market trends indicate a 7.2% CAGR (2023–2030), driven by diabetes and congenital hyperinsulinism applications. Key selection criteria include purity (>98%), cold-chain logistics compliance (2–8°C), and FDA/EMA certifications. Leading brands prioritize rapid onset (10–15 min) and shelf-life (24–36 months). Industry challenges include high production costs and limited oral bioavailability, favoring injectable peptides.